|
DE69834268T2
(de)
|
1997-12-22 |
2007-04-12 |
Euro-Celtique S.A. |
Peroral zu verabreichende Arzneiform enthaltend eine Kombination von einem Opioid Agonisten und Naltrexon
|
|
US6375957B1
(en)
*
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
RU2228180C2
(ru)
*
|
1997-12-22 |
2004-05-10 |
Эро-Селтик, С.А. |
Способ предотвращения злоупотребления содержащими опиоиды лекарственными формами
|
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
|
KR100889069B1
(ko)
|
1999-10-29 |
2009-03-17 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
|
BRPI0108380B8
(pt)
|
2000-02-08 |
2021-05-25 |
Euro Celtique S/A |
fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor
|
|
HU230686B1
(en)
|
2000-10-30 |
2017-08-28 |
Euro Celtique Sa |
Controlled release hydrocodone compositions
|
|
US7858118B2
(en)
*
|
2001-04-11 |
2010-12-28 |
Galephar Pharmaceutical Research, Inc. |
Extended release composition containing Tramadol
|
|
AU2002303718B2
(en)
*
|
2001-05-11 |
2008-02-28 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant opioid dosage form
|
|
JP4522652B2
(ja)
*
|
2001-05-11 |
2010-08-11 |
エンドー ファーマシューティカルズ， インコーポレイティド |
乱用防止制御放出オピオイド投薬形態
|
|
US7968119B2
(en)
*
|
2001-06-26 |
2011-06-28 |
Farrell John J |
Tamper-proof narcotic delivery system
|
|
ES2284888T3
(es)
|
2001-07-06 |
2007-11-16 |
Endo Pharmaceuticals Inc. |
Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico.
|
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
|
DK1404331T3
(da)
|
2001-07-06 |
2008-01-28 |
Penwest Pharmaceuticals Co |
Sustained release-formuleringer af oxymorphon
|
|
US7943173B2
(en)
*
|
2001-07-18 |
2011-05-17 |
Purdue Pharma L.P. |
Pharmaceutical combinations of oxycodone and naloxone
|
|
US20030157168A1
(en)
*
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
|
US7141250B2
(en)
*
|
2001-08-06 |
2006-11-28 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing bittering agent
|
|
US7144587B2
(en)
*
|
2001-08-06 |
2006-12-05 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
|
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
|
US7332182B2
(en)
*
|
2001-08-06 |
2008-02-19 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
|
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
US7157103B2
(en)
|
2001-08-06 |
2007-01-02 |
Euro-Celtique S.A. |
Pharmaceutical formulation containing irritant
|
|
KR20040029405A
(ko)
|
2001-08-06 |
2004-04-06 |
유로-셀티크 소시에떼 아노뉨 |
방출성 및 격리된 길항제와 오피오이드 효능제의 제제
|
|
US20030049317A1
(en)
*
|
2001-08-30 |
2003-03-13 |
Lindsay David R. |
Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations
|
|
WO2003026743A2
(en)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
|
DK2939696T3
(en)
|
2001-10-18 |
2016-05-23 |
Nektar Therapeutics |
Polymer Conjugates of Opioid Antagonists
|
|
EP1450824A4
(en)
*
|
2001-11-02 |
2005-09-28 |
Elan Corp Plc |
PHARMACEUTICAL COMPOSITION
|
|
US20060177381A1
(en)
*
|
2002-02-15 |
2006-08-10 |
Howard Brooks-Korn |
Opiopathies
|
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
|
CA2477004C
(en)
*
|
2002-02-22 |
2011-05-10 |
Thomas Piccariello |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
|
AU2003220290B2
(en)
*
|
2002-03-14 |
2007-06-14 |
Euro-Celtique S.A. |
Naltrexone hydrochloride compositions
|
|
GB0206505D0
(en)
*
|
2002-03-19 |
2002-05-01 |
Euro Celtique Sa |
Pharmaceutical combination
|
|
US7666876B2
(en)
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
|
US7790215B2
(en)
*
|
2002-03-26 |
2010-09-07 |
Purdue Pharma Lp |
Sustained-release gel coated compositions
|
|
EP2316429A1
(en)
*
|
2002-04-05 |
2011-05-04 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
|
CA2480824A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
|
EP1492511B3
(fr)
|
2002-04-09 |
2012-05-02 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
|
NZ535971A
(en)
|
2002-04-23 |
2007-07-27 |
Alza Corp |
Transdermal analgesic patch with reduced abuse potential
|
|
US20040156844A1
(en)
*
|
2002-05-22 |
2004-08-12 |
Curtis Wright |
Tamper resistant oral dosage form
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
|
WO2004004693A1
(en)
*
|
2002-07-05 |
2004-01-15 |
Collgegium Pharmaceutical |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US20060110333A1
(en)
*
|
2002-07-11 |
2006-05-25 |
Taiho Pharmaceutical Co., Ltd. |
Composition for nasal absorption
|
|
US8679533B2
(en)
|
2002-07-25 |
2014-03-25 |
Pharmacia Corporation |
Pramipexole once-daily dosage form
|
|
DE10237056A1
(de)
*
|
2002-08-09 |
2004-03-04 |
Grünenthal GmbH |
Opiod-Rezeptor-Antagonisten in Transdermalen Systemen mit Buprenorphin
|
|
ATE491439T1
(de)
|
2002-08-15 |
2011-01-15 |
Euro Celtique Sa |
Pharmazeutische zusammensetzungen enthaltend einen opioidantagonisten
|
|
US7815934B2
(en)
|
2002-09-20 |
2010-10-19 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
|
CA2498798A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sustained-release opioid formulations and methods of use
|
|
US8623412B2
(en)
*
|
2002-09-23 |
2014-01-07 |
Elan Pharma International Limited |
Abuse-resistant pharmaceutical compositions
|
|
DE10250084A1
(de)
*
|
2002-10-25 |
2004-05-06 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
US9233049B2
(en)
|
2002-10-31 |
2016-01-12 |
Purdue Pharma L.P. |
Pharmaceutical identification
|
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
|
US7524515B2
(en)
|
2003-01-10 |
2009-04-28 |
Mutual Pharmaceuticals, Inc. |
Pharmaceutical safety dosage forms
|
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
|
DE10305137A1
(de)
*
|
2003-02-07 |
2004-08-26 |
Novosis Ag |
Transdermale therapeutische Abgabesysteme mit einem Butenolid
|
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
AU2004232370B2
(en)
*
|
2003-04-21 |
2009-12-10 |
Euro-Celtique S.A. |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
SI2316456T1
(sl)
|
2003-04-29 |
2017-10-30 |
Orexigen Therapeutics, Inc. |
Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
|
|
US8778382B2
(en)
*
|
2003-04-30 |
2014-07-15 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
|
CA2529984C
(en)
*
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
EP1658054B1
(de)
*
|
2003-08-06 |
2007-06-27 |
Grünenthal GmbH |
Gegen missbrauch gesicherte darreichungsform
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
EP2298303A1
(en)
*
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
|
JP4758897B2
(ja)
*
|
2003-09-25 |
2011-08-31 |
ユーロ−セルティーク エス．エイ． |
ヒドロコドンとナルトレキソンとの併用医薬
|
|
US20050245557A1
(en)
*
|
2003-10-15 |
2005-11-03 |
Pain Therapeutics, Inc. |
Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
|
|
AU2004281153A1
(en)
*
|
2003-10-15 |
2005-04-28 |
Pain Therapeutics, Inc. |
Treatment of arthritic conditions, chronic inflammation or pain
|
|
CA2543610A1
(en)
|
2003-10-30 |
2005-05-19 |
Alza Corporation |
Transdermal analgesic systems having reduced abuse potential
|
|
DK1691892T3
(da)
*
|
2003-12-09 |
2007-06-25 |
Euro Celtique Sa |
Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme
|
|
US8883204B2
(en)
*
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
|
TWI350762B
(en)
*
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
|
ME02661B
(me)
*
|
2004-02-23 |
2017-06-20 |
Euro Celtique Sa |
Opioidni transdermalni preparat otporan na zloupotrebu
|
|
PL1729730T3
(pl)
*
|
2004-03-30 |
2009-06-30 |
Euro Celtique Sa |
Odporna na zniszczenie postać dawkowania zawierająca adsorbent i środek przeciwdziałający
|
|
TW201509943A
(zh)
|
2004-03-30 |
2015-03-16 |
Euro Celtique Sa |
含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
ES2653568T3
(es)
|
2004-06-12 |
2018-02-07 |
Collegium Pharmaceutical, Inc. |
Formulaciones de fármacos para la prevención del abuso
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
BRPI0513848A
(pt)
|
2004-08-13 |
2008-05-20 |
Boehringer Ingelheim Int |
formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
|
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
|
US20070259045A1
(en)
*
|
2005-01-28 |
2007-11-08 |
Euro-Celtique S.A. |
Alcohol Resistant Dosage Forms
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
FR2881652B1
(fr)
*
|
2005-02-08 |
2007-05-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale microparticulaire anti-mesuage
|
|
FR2889810A1
(fr)
*
|
2005-05-24 |
2007-02-23 |
Flamel Technologies Sa |
Forme medicamenteuse orale, microparticulaire, anti-mesurage
|
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
|
EP1879557A1
(en)
*
|
2005-05-13 |
2008-01-23 |
Alpharma, Inc. |
Morphine sulfate formulations
|
|
EP2316437B1
(en)
|
2005-05-13 |
2014-07-30 |
Alza Corporation |
Multilayer drug delivery system with barrier against reservoir material flow
|
|
CA2608361A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Alpharma, Inc. |
Morphine sulphate formulations
|
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
|
WO2006133733A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Flamel Technologies |
Oral dosage form comprising an antimisuse system
|
|
EP1909769A2
(en)
*
|
2005-08-01 |
2008-04-16 |
Alpharma, Inc. |
Alcohol resistant pharmaceutical formulations
|
|
JP5164840B2
(ja)
|
2005-08-02 |
2013-03-21 |
ソル − ゲル テクノロジーズ リミテッド |
水不溶性成分の金属酸化物被覆
|
|
US8329744B2
(en)
*
|
2005-11-02 |
2012-12-11 |
Relmada Therapeutics, Inc. |
Methods of preventing the serotonin syndrome and compositions for use thereof
|
|
US9125833B2
(en)
*
|
2005-11-02 |
2015-09-08 |
Relmada Therapeutics, Inc. |
Multimodal abuse resistant and extended release opioid formulations
|
|
US20090082466A1
(en)
*
|
2006-01-27 |
2009-03-26 |
Najib Babul |
Abuse Resistant and Extended Release Formulations and Method of Use Thereof
|
|
US8652529B2
(en)
|
2005-11-10 |
2014-02-18 |
Flamel Technologies |
Anti-misuse microparticulate oral pharmaceutical form
|
|
CN101370488B
(zh)
|
2005-11-22 |
2012-07-18 |
奥雷西根治疗公司 |
增加胰岛素敏感性的组合物
|
|
AU2006326377B2
(en)
*
|
2005-12-13 |
2010-10-07 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
|
EP1810714A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
|
|
EP1810678A1
(de)
*
|
2006-01-19 |
2007-07-25 |
Holger Lars Hermann |
Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
|
|
RU2433817C2
(ru)
*
|
2006-01-21 |
2011-11-20 |
Эбботт Гмбх Унд Ко.Кг |
Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ
|
|
US20070185145A1
(en)
*
|
2006-02-03 |
2007-08-09 |
Royds Robert B |
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
|
|
US7939567B2
(en)
*
|
2006-02-24 |
2011-05-10 |
Blue Blood Biotech Corp. |
Dextromethorphan-based method for treating acne
|
|
ZA200807571B
(en)
*
|
2006-03-01 |
2009-08-26 |
Ethypharm Sa |
Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
|
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
|
KR101495146B1
(ko)
|
2006-03-16 |
2015-02-24 |
트리스 파마 인코포레이티드 |
약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
|
|
GB0606124D0
(en)
*
|
2006-03-28 |
2006-05-03 |
Reckitt Benckiser Healthcare |
Buprenorphine derivatives and uses thereof
|
|
CN104825397A
(zh)
*
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
|
JP2009535409A
(ja)
*
|
2006-05-03 |
2009-10-01 |
コーワ ファーマシューティカルズ アメリカ，インコーポレイティド |
即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬
|
|
US10960077B2
(en)
*
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
|
ATE552829T1
(de)
*
|
2006-06-19 |
2012-04-15 |
Alpharma Pharmaceuticals Llc |
Pharmazeutische zusammensetzungen
|
|
US8765178B2
(en)
|
2006-07-19 |
2014-07-01 |
Watson Laboratories, Inc. |
Controlled release formulations and associated methods
|
|
JP5448814B2
(ja)
*
|
2006-07-21 |
2014-03-19 |
バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド |
取り込みを増強する経粘膜送達装置
|
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
|
AU2011205222B2
(en)
*
|
2006-07-21 |
2014-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
|
WO2008027442A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Theraquest Biosciences, Llc |
Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
|
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
|
US8187636B2
(en)
*
|
2006-09-25 |
2012-05-29 |
Atlantic Pharmaceuticals, Inc. |
Dosage forms for tamper prone therapeutic agents
|
|
WO2008063301A2
(en)
*
|
2006-10-11 |
2008-05-29 |
Alpharma, Inc. |
Pharmaceutical compositions
|
|
WO2008060964A2
(en)
|
2006-11-09 |
2008-05-22 |
Orexigen Therapeutics, Inc. |
Unit dosage package and methods for administering weight loss medications
|
|
DE102006054731B4
(de)
|
2006-11-21 |
2013-02-28 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
|
|
SI2101740T1
(sl)
|
2006-12-04 |
2014-03-31 |
Orexo Ab |
Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode
|
|
BRPI0808163A2
(pt)
|
2007-02-01 |
2014-11-04 |
Sol Gel Technologies Ltd |
Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit
|
|
EP2545776A3
(en)
|
2007-02-01 |
2014-12-24 |
Sol-Gel Technologies Ltd. |
Method for preparing particles comprising metal oxide coating and particles with metal oxide coating
|
|
GB2447014A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
|
ATE476176T1
(de)
*
|
2007-03-02 |
2010-08-15 |
Farnam Co Inc |
Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
|
PL2187873T3
(pl)
|
2007-08-13 |
2019-01-31 |
Abuse Deterrent Pharmaceutical Llc |
Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
|
|
MX2010002409A
(es)
*
|
2007-09-03 |
2010-05-19 |
Nanotherapeutics Inc |
Composiciones y metodos para la distribucion de farmacos escasamente solubles.
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
AU2015200313B2
(en)
*
|
2007-12-17 |
2016-12-01 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
EP2224806A4
(en)
*
|
2007-12-17 |
2014-02-19 |
Alpharma Pharmaceuticals Llc |
PHARMACEUTICAL COMPOSITION
|
|
WO2009079521A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
AU2008343267A1
(en)
*
|
2007-12-17 |
2009-07-09 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
CA2707980C
(en)
*
|
2007-12-17 |
2015-05-12 |
Labopharm Inc. |
Misuse preventative, controlled release formulation
|
|
CA2709992A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Abuse resistant pharmaceutical compositions of opiod agonists
|
|
WO2009092601A1
(en)
|
2008-01-25 |
2009-07-30 |
Grünenthal GmbH |
Pharmaceutical dosage form
|
|
US9700552B2
(en)
|
2008-02-28 |
2017-07-11 |
Syntropharma Limited |
Pharmaceutical compositions for treatment of addiction
|
|
NZ588863A
(en)
|
2008-05-09 |
2012-08-31 |
Gruenenthal Chemie |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
|
JP2011521973A
(ja)
|
2008-05-30 |
2011-07-28 |
オレキシジェン・セラピューティクス・インコーポレーテッド |
内臓脂肪の状態を処置するための方法
|
|
US20110177133A1
(en)
*
|
2008-07-07 |
2011-07-21 |
Michael Hopp |
Use of opioid antagonists for treating urinary retention
|
|
WO2010044842A1
(en)
*
|
2008-10-16 |
2010-04-22 |
University Of Tennessee Research Foundation |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
MX2011004455A
(es)
|
2008-10-30 |
2011-05-25 |
Gruenenthal Gmbh |
Formas de dosificacion del tapentadol novedosas y potentes.
|
|
EP2379111B1
(en)
*
|
2008-12-12 |
2013-03-20 |
Paladin Labs Inc. |
Narcotic drug formulations with decreased abuse potential
|
|
JP5667575B2
(ja)
|
2008-12-16 |
2015-02-12 |
パラディン ラブス インコーポレーテッド |
誤用を防止する放出制御製剤
|
|
CA2750144C
(en)
|
2008-12-31 |
2016-10-25 |
Upsher-Smith Laboratories, Inc. |
Opioid-containing oral pharmaceutical compositions and methods
|
|
DK3045043T3
(da)
*
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
|
|
PL2405915T3
(pl)
|
2009-03-10 |
2019-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
|
|
CA2759870A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Lars Holger Hermann |
Particulate pharmaceutical composition with an opioid and an opioid antagonist
|
|
GB0909680D0
(en)
|
2009-06-05 |
2009-07-22 |
Euro Celtique Sa |
Dosage form
|
|
ES2718688T3
(es)
|
2009-07-22 |
2019-07-03 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
|
|
JP5667183B2
(ja)
|
2009-07-22 |
2015-02-12 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
加熱溶融押出成型した制御放出性投与剤型
|
|
EP2477610A1
(en)
|
2009-09-17 |
2012-07-25 |
Upsher-Smith Laboratories, Inc. |
A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
|
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
|
US9248123B2
(en)
|
2010-01-11 |
2016-02-02 |
Orexigen Therapeutics, Inc. |
Methods of providing weight loss therapy in patients with major depression
|
|
CN102821757B
(zh)
|
2010-02-03 |
2016-01-20 |
格吕伦塔尔有限公司 |
通过挤出机制备粉末状药物组合物
|
|
US20120321716A1
(en)
|
2011-02-17 |
2012-12-20 |
Michael Vachon |
Technology for preventing abuse of solid dosage forms
|
|
US9277748B2
(en)
|
2010-03-12 |
2016-03-08 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Agonist/antagonist compositions and methods of use
|
|
CN102946870A
(zh)
*
|
2010-05-10 |
2013-02-27 |
欧洲凯尔特公司 |
包含氢吗啡酮和纳洛酮的药物组合物
|
|
KR101479388B1
(ko)
*
|
2010-05-10 |
2015-01-05 |
유로-셀티큐 에스.에이. |
활성제 로딩된 과립과 추가의 활성제와의 조합물
|
|
US9993433B2
(en)
*
|
2010-05-10 |
2018-06-12 |
Euro-Celtique S.A. |
Manufacturing of active-free granules and tablets comprising the same
|
|
CA2798702A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholresistant metoprolol-containing extended-release oral dosage forms
|
|
US9636303B2
(en)
|
2010-09-02 |
2017-05-02 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising an anionic polymer
|
|
CN103269688A
(zh)
|
2010-09-02 |
2013-08-28 |
格吕伦塔尔有限公司 |
包含无机盐的抗破碎剂型
|
|
DE102010048883A1
(de)
|
2010-10-19 |
2012-04-19 |
Lars Holger Hermann |
Verwendung von Buprenorphin zum Abususschutz von Opiat-Vollagonisten sowie entsprechende pharmazeutische Zusammensetzungen
|
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
|
JP2012087101A
(ja)
*
|
2010-10-21 |
2012-05-10 |
Holger Hermann Lars |
オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
|
|
AU2011346757B2
(en)
|
2010-12-22 |
2015-08-20 |
Purdue Pharma L.P. |
Encased tamper resistant controlled release dosage forms
|
|
PH12013501345A1
(en)
|
2010-12-23 |
2022-10-24 |
Purdue Pharma Lp |
Tamper resistant solid oral dosage forms
|
|
TWI554271B
(zh)
*
|
2010-12-28 |
2016-10-21 |
歐 賽提克股份有限公司 |
用於治療巴金森氏症的類鴉片激動劑與類鴉片拮抗劑之組合
|
|
CN102068697B
(zh)
*
|
2010-12-30 |
2013-10-16 |
宜昌人福药业有限责任公司 |
含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
|
|
AU2012213056A1
(en)
|
2011-02-02 |
2013-07-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition comprising opioid agonist and sequestered antagonist
|
|
WO2013003845A1
(en)
*
|
2011-06-30 |
2013-01-03 |
Neos Therapeutics, Lp |
Abuse resistant drug forms
|
|
EP2736495B1
(en)
|
2011-07-29 |
2017-08-23 |
Grünenthal GmbH |
Tamper-resistant tablet providing immediate drug release
|
|
NO2736497T3
(enExample)
|
2011-07-29 |
2018-01-20 |
|
|
|
SG10201610097WA
(en)
|
2011-08-18 |
2017-01-27 |
Biodelivery Sciences Int Inc |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
|
RS62505B1
(sr)
|
2011-09-19 |
2021-11-30 |
Orexo Ab |
Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
|
|
TW201336529A
(zh)
*
|
2011-12-09 |
2013-09-16 |
Purdue Pharma Lp |
包含聚（ε－己內酯）和聚氧化乙烯之藥物劑量型
|
|
BR112014014137A2
(pt)
|
2011-12-12 |
2017-06-13 |
Lts Lohmann Therapie Systeme Ag |
sistema de liberação transdérmica compreendendo buprenorfina
|
|
CN110123792A
(zh)
|
2011-12-21 |
2019-08-16 |
拜欧帝力威瑞科学有限公司 |
用于慢性疼痛缓解的跨粘膜药物传递装置
|
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
|
MX356421B
(es)
|
2012-02-28 |
2018-05-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
|
|
US9687445B2
(en)
|
2012-04-12 |
2017-06-27 |
Lts Lohmann Therapie-Systeme Ag |
Oral film containing opiate enteric-release beads
|
|
KR102196741B1
(ko)
|
2012-04-17 |
2020-12-30 |
퍼듀 퍼머 엘피 |
오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
|
|
TR201815502T4
(tr)
|
2012-04-18 |
2018-11-21 |
Gruenenthal Gmbh |
Kurcalama veya dirençli ve doz boşalımına dirençli farmasötik dozaj formu.
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
US9956237B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9700570B2
(en)
|
2014-05-27 |
2017-07-11 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10039773B2
(en)
|
2012-05-14 |
2018-08-07 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating arthritis
|
|
US9427403B2
(en)
|
2012-05-14 |
2016-08-30 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US10463682B2
(en)
|
2012-05-14 |
2019-11-05 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
|
|
US9616078B2
(en)
|
2012-05-14 |
2017-04-11 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9694023B2
(en)
|
2012-05-14 |
2017-07-04 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9867840B2
(en)
|
2014-05-27 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9956238B2
(en)
|
2014-05-15 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9795622B2
(en)
|
2012-05-14 |
2017-10-24 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating pain associated with a joint
|
|
US10413560B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9999629B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9827256B2
(en)
|
2014-05-27 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating lower back pain
|
|
US9956234B2
(en)
|
2012-05-14 |
2018-05-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US9211257B2
(en)
|
2012-05-14 |
2015-12-15 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9820999B2
(en)
|
2012-05-14 |
2017-11-21 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10080765B2
(en)
|
2012-05-14 |
2018-09-25 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US9789128B2
(en)
|
2012-05-14 |
2017-10-17 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9925203B2
(en)
|
2012-05-14 |
2018-03-27 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9827192B2
(en)
|
2012-05-14 |
2017-11-28 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9770457B2
(en)
|
2012-05-14 |
2017-09-26 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesion
|
|
US10034890B2
(en)
|
2012-05-14 |
2018-07-31 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9949993B2
(en)
|
2012-05-14 |
2018-04-24 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US9675626B2
(en)
|
2012-05-14 |
2017-06-13 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9844559B2
(en)
|
2012-05-14 |
2017-12-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating bone marrow lesions
|
|
US9877977B2
(en)
|
2012-05-14 |
2018-01-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9895383B2
(en)
|
2012-05-14 |
2018-02-20 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9782421B1
(en)
|
2012-05-14 |
2017-10-10 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US10493085B2
(en)
|
2012-05-14 |
2019-12-03 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US9707247B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Compositions for administration of zoledronic acid or related compounds for treating low back pain
|
|
US10413561B2
(en)
|
2012-05-14 |
2019-09-17 |
Antecip Bioventures Ii Llc |
Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
|
|
US8865757B1
(en)
|
2014-05-28 |
2014-10-21 |
Antecip Bioventures Ii Llp |
Therapeutic compositions comprising imidazole and imidazolium compounds
|
|
US10028908B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9867839B2
(en)
|
2012-05-14 |
2018-01-16 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for joint conditions
|
|
US10092581B2
(en)
|
2014-05-15 |
2018-10-09 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9901589B2
(en)
|
2012-05-14 |
2018-02-27 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9662343B2
(en)
|
2012-05-14 |
2017-05-30 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US10004756B2
(en)
|
2014-05-15 |
2018-06-26 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9943531B2
(en)
|
2014-08-08 |
2018-04-17 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US10028969B2
(en)
|
2012-05-14 |
2018-07-24 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US8802658B2
(en)
|
2012-05-14 |
2014-08-12 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US9655908B2
(en)
|
2012-05-14 |
2017-05-23 |
Antecip Bioventures Ii Llc |
Neridronic acid molecular complex for treating complex regional pain syndrome
|
|
US10173986B2
(en)
|
2012-05-14 |
2019-01-08 |
Antecip Bioventures Ii Llc |
Methods for the safe administration of imidazole or imidazolium compounds
|
|
US9289441B2
(en)
|
2014-08-08 |
2016-03-22 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors such as zoledronic acid for low back pain treatment
|
|
US9707245B2
(en)
|
2012-05-14 |
2017-07-18 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10111837B2
(en)
|
2012-05-14 |
2018-10-30 |
Antecip Bioventures Ii Llc |
Dosage forms for oral administration of zoledronic acid or related compounds
|
|
US9861648B2
(en)
|
2012-05-14 |
2018-01-09 |
Antecip Boiventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
US9669040B2
(en)
|
2012-05-14 |
2017-06-06 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US11654152B2
(en)
|
2012-05-14 |
2023-05-23 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating disease
|
|
US10016445B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
|
|
US9999628B2
(en)
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10350227B2
(en)
|
2012-05-14 |
2019-07-16 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
US10016446B2
(en)
|
2012-05-14 |
2018-07-10 |
Antecip Bioventures Ii Llc |
Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
|
|
US9717747B2
(en)
|
2012-05-14 |
2017-08-01 |
Antecip Bioventures Ii Llc |
Osteoclast inhibitors for knee conditions
|
|
PE20150358A1
(es)
|
2012-06-06 |
2015-04-06 |
Orexigen Therapeutics Inc |
Metodos para el tratamiento del sobrepeso y de la obesidad
|
|
JP6031599B2
(ja)
|
2012-07-12 |
2016-11-24 |
マリンクロッド エルエルシー |
長期放出性、濫用抑止特性薬学的組成物
|
|
US9687465B2
(en)
|
2012-11-27 |
2017-06-27 |
Sol-Gel Technologies Ltd. |
Compositions for the treatment of rosacea
|
|
KR101659983B1
(ko)
|
2012-12-31 |
2016-09-26 |
주식회사 삼양바이오팜 |
용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
|
|
CN105120846B
(zh)
|
2013-02-05 |
2019-10-18 |
普渡制药公司 |
抗篡改的药物制剂
|
|
CA2907428A1
(en)
|
2013-03-15 |
2014-09-18 |
Inspirion Delivery Technologies, Llc |
Abuse deterrent compositions and methods of use
|
|
US9517208B2
(en)
|
2013-03-15 |
2016-12-13 |
Purdue Pharma L.P. |
Abuse-deterrent dosage forms
|
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
|
ITTO20130284A1
(it)
*
|
2013-04-09 |
2014-10-10 |
Fond Istituto Italiano Di Tecnologia |
Procedimento per la produzione di microparticelle polimeriche sagomate
|
|
US10154966B2
(en)
*
|
2013-05-29 |
2018-12-18 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
|
HK1222135A1
(zh)
|
2013-06-04 |
2017-06-23 |
Lts Lohmann Therapie-Systeme Ag |
透皮递送系统
|
|
CN105682643B
(zh)
|
2013-07-12 |
2019-12-13 |
格吕伦塔尔有限公司 |
含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
|
|
MY183489A
(en)
|
2013-07-23 |
2021-02-22 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
|
JP2016535778A
(ja)
|
2013-10-31 |
2016-11-17 |
シーマ・ラブス・インコーポレーテッド |
乱用抑止性剤形
|
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EA030310B1
(ru)
|
2013-11-13 |
2018-07-31 |
Эро-Селтик С.А. |
Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
|
|
JP6480936B2
(ja)
|
2013-11-26 |
2019-03-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
クライオミリングによる粉末状医薬組成物の調製
|
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|
|
US9480644B2
(en)
|
2014-03-14 |
2016-11-01 |
Opiant Pharmaceuticals, Inc. |
Nasal drug products and methods of their use
|
|
US9211253B2
(en)
|
2014-03-14 |
2015-12-15 |
Lightlake Therapeutics Inc. |
Nasal drug products and methods of their use
|
|
US9561177B2
(en)
|
2014-03-14 |
2017-02-07 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
US10085937B2
(en)
|
2014-03-14 |
2018-10-02 |
Adapt Pharma Limited |
Nasal drug products and methods of their use
|
|
EP3142646A1
(en)
|
2014-05-12 |
2017-03-22 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
JP2017516789A
(ja)
|
2014-05-26 |
2017-06-22 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エタノール過量放出に対して防護されている多粒子
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
|
US10493027B2
(en)
|
2014-08-07 |
2019-12-03 |
Mucodel Pharma Llc |
Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
|
|
WO2016022816A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Mucodel Pharma Llc |
Chemically stable and oromucosally absorbable gel compositions of a pharmaceutical active agent in a multi-chambered delivery system
|
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
|
EP3229788A4
(en)
|
2014-12-08 |
2018-06-13 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3229785A2
(de)
*
|
2014-12-08 |
2017-10-18 |
Develco Pharma Schweiz AG |
Naloxon-monopräparat und mehrschichttablette
|
|
FR3032353B1
(fr)
|
2015-02-06 |
2017-03-10 |
Jacques Seguin |
Composition pharmaceutique et dispositif pour le traitement de la douleur
|
|
HK1246173A1
(zh)
|
2015-04-24 |
2018-09-07 |
Grünenthal GmbH |
具有立即释放和对溶剂萃取的抗性的抗篡改剂型
|
|
EP3288556A4
(en)
|
2015-04-29 |
2018-09-19 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
|
CA2996281C
(en)
*
|
2015-08-31 |
2022-03-08 |
Regents Of The University Of Minnesota |
Opioid receptor modulators and use thereof
|
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
|
JP2018526409A
(ja)
*
|
2015-09-09 |
2018-09-13 |
マイセル・テクノロジーズ，インコーポレイテッド |
Ｍｉｃｅｌｌ技術のバイオ医薬品への適用
|
|
US10842750B2
(en)
|
2015-09-10 |
2020-11-24 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
US9861629B1
(en)
|
2015-10-07 |
2018-01-09 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
|
GB201520390D0
(en)
*
|
2015-11-19 |
2016-01-06 |
Euro Celtique Sa |
Composition
|
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
|
US10532385B2
(en)
|
2016-06-29 |
2020-01-14 |
Disposerx, Inc. |
Disposal of medicaments
|
|
WO2018012627A1
(ja)
*
|
2016-07-15 |
2018-01-18 |
シャープ株式会社 |
送風装置および空気調和機
|
|
WO2018208241A1
(en)
*
|
2017-05-10 |
2018-11-15 |
İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi |
Formulation and optimization of controlled release tablets of morphine sulphate
|
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
|
AU2018291397A1
(en)
|
2017-06-30 |
2020-01-16 |
Purdue Pharma L.P. |
Method of treatment and dosage forms thereof
|
|
EP3651756B1
(en)
|
2017-07-12 |
2025-09-03 |
Sol-Gel Technologies Ltd. |
Compositions comprising encapsulated tretinoin
|
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
|
US12458592B1
(en)
|
2017-09-24 |
2025-11-04 |
Tris Pharma, Inc. |
Extended release amphetamine tablets
|
|
IL273904B2
(en)
*
|
2017-10-09 |
2024-08-01 |
Rhodes Pharmaceuticals Lp |
Medicinal resin components and methods for their production and use
|
|
EP3473246A1
(en)
|
2017-10-19 |
2019-04-24 |
Capsugel Belgium NV |
Immediate release abuse deterrent formulations
|
|
AU2018351502B2
(en)
*
|
2017-10-20 |
2024-09-05 |
Purdue Pharma L.P. |
Pharmaceutical dosage forms
|
|
US12161754B2
(en)
|
2017-12-20 |
2024-12-10 |
Purdue Pharma L.P. |
Abuse deterrent morphine sulfate dosage forms
|
|
US10624856B2
(en)
|
2018-01-31 |
2020-04-21 |
Dharma Laboratories LLC |
Non-extractable oral solid dosage forms
|
|
CN109232748B
(zh)
*
|
2018-09-26 |
2019-06-11 |
哈尔滨工业大学 |
多位点修饰的脑啡肽与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
|
|
US20220105085A1
(en)
*
|
2019-01-31 |
2022-04-07 |
Relmada Therapeutics, Inc. |
Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist
|
|
US11324707B2
(en)
|
2019-05-07 |
2022-05-10 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
MX2022000297A
(es)
*
|
2019-07-10 |
2022-04-25 |
Intas Pharmaceuticals Ltd |
Formulacion de naltrexona.
|
|
IT201900013473A1
(it)
*
|
2019-07-31 |
2021-01-31 |
Vetagro Int S R L |
Composizioni comprendenti amminoacidi e un ulteriore componente per l'apporto di amminoacidi ad un animale monogastrico quale uomo o maiale
|
|
EP3936112A1
(en)
*
|
2020-07-07 |
2022-01-12 |
Occlugel |
Hydrophilic degradable microspheres for delivering buprenorphine
|
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
|
CA3247111A1
(en)
*
|
2022-01-26 |
2023-08-03 |
Aardvark Therapeutics, Inc. |
Extended-release oral formulation of liquid resin for the treatment of autism spectrum disorders
|
|
US12303604B1
(en)
|
2024-10-16 |
2025-05-20 |
Currax Pharmaceuticals Llc |
Pharmaceutical formulations comprising naltrexone and/or bupropion
|